Jun 17 |
EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma
|
Jun 16 |
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
|
Jun 14 |
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea
|
Jun 14 |
Regeneron wins injunction blocking Samsung Bioepis from launching generic Eylea
|
Jun 14 |
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past five years
|
Jun 13 |
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
|
Jun 13 |
REGN, CI, BSX: Which “Strong Buy” Healthcare Stock Is the Best Bet?
|
Jun 12 |
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
|
Jun 11 |
Regeneron wins injunction blocking Mylan from launching generic version of its eye drug Eylea (update)
|
Jun 11 |
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
|